Table 1

Selected characteristics among breast cancer cases by hormone receptor status: SEER program, 1990–2001

ER+PR+
 ER+PR-
 ER-PR+
 ER-PR-

(n = 98,463)
 (n = 19,886)
 (n = 4,896)
 (n = 31,930)

Characteristics
 n
 Column %
 Row %
 n
 Column %
 Row %
 n
 Column %
 Row %
 n
 Column %
 Row %
Age at diagnosis, years











     30–39
 4,903
 5.0
 49.5
 885
 4.5
 8.9
 569
 11.6
 5.7
 3,558
 11.1
 35.9
     40–49
 18,575
 18.9
 60.9
 2,490
 12.5
 8.2
 1,508
 30.8
 4.9
 7,929
 24.8
 26.0
     50–59
 21,807
 22.1
 61.4
 4,464
 22.5
 12.5
 1,161
 23.7
 3.3
 8,094
 25.4
 22.8
     60–69
 22,019
 22.4
 65.9
 4,752
 23.9
 14.2
 801
 16.4
 2.4
 5,856
 18.3
 17.5
     70–79
 20,667
 21.0
 68.2
 4,662
 23.4
 15.4
 584
 11.9
 1.9
 4,401
 13.8
 14.5
     ≥80
 10,492
 10.6
 67.7
 2,633
 13.2
 17.0
 273
 5.6
 1.8
 2,092
 6.6
 13.5
Diagnosis year











     1990–1992
 16,500
 16.8
 61.6
 3,751
 18.9
 14.0
 1,111
 22.7
 4.1
 5,435
 17.0
 20.3
     1993–1995
 22,087
 22.4
 61.7
 4,514
 22.7
 12.6
 1,485
 30.3
 4.1
 7,728
 24.2
 21.6
     1996–1998
 27,734
 28.2
 64.2
 5,239
 26.3
 12.1
 1,367
 27.9
 3.2
 8,884
 27.8
 20.5
     1999–2001
 32,142
 32.6
 65.2
 6,382
 32.1
 12.9
 933
 19.1
 1.9
 9,883
 31.0
 20.0
SEER registry











     Atlanta, GA
 5,696
 5.8
 59.4
 1,171
 5.9
 12.2
 381
 7.8
 4
 2,344
 7.3
 24.4
     Connecticut
 11,093
 11.3
 61.4
 2,448
 12.3
 13.6
 602
 12.3
 3.3
 3,914
 12.3
 21.7
     Detroit, MI
 10,559
 10.7
 60.4
 2,314
 11.6
 13.2
 539
 11
 3.1
 4,063
 12.7
 23.3
     Hawaii
 4,149
 4.2
 67.0
 703
 3.5
 11.3
 273
 5.6
 4.4
 1,072
 3.4
 17.3
     Iowa
 10,238
 10.4
 65.2
 1,914
 9.6
 12.2
 530
 10.8
 3.4
 3,017
 9.4
 19.2
     Los Angeles, CA
 15,586
 15.8
 61.4
 3,399
 17.1
 13.4
 919
 18.8
 3.6
 5,491
 17.2
 21.6
     New Mexico
 4,066
 4.1
 61.8
 885
 4.5
 13.5
 193
 3.9
 2.9
 1,435
 4.5
 21.8
     San Francisco-Oakland, CA
 13,063
 13.3
 63.9
 2,750
 13.8
 13.5
 652
 13.3
 3.2
 3,957
 12.4
 19.4
     San Jose, CA
 5,474
 5.5
 65.3
 1,134
 5.7
 13.5
 228
 4.7
 2.7
 1,548
 4.9
 18.5
     Seattle, WA
 14,241
 14.5
 68
 2,517
 12.7
 12.0
 423
 8.6
 2.0
 3,770
 11.8
 18.0
     Utah
 4,298
 4.4
 66.9
 651
 3.3
 10.1
 156
 3.2
 2.5
 1,319
 4.1
 20.5
Race











     Non-Hispanic white
 78,805
 81.7
 65.4
 15,716
 80.5
 13.0
 3,515
 73.5
 2.9
 22,532
 72.1
 18.7
     African-American
 5,724
 5.9
 48.0
 1,488
 7.6
 12.5
 504
 10.5
 4.2
 4,206
 13.5
 35.3
     Native American
 284
 0.3
 55.0
 57
 0.3
 11.0
 23
 0.5
 4.5
 152
 0.5
 29.5
     Asian/Pacific Islander
 6,065
 6.3
 65.1
 1,061
 5.4
 11.4
 382
 8.0
 4.1
 1,805
 5.8
 19.4
     Hispanic white
 5,585
 5.8
 57.8
 1,203
 6.2
 12.4
 359
 7.5
 3.7
 2,524
 8.1
 26.1
     Other/Unknown
 2,000
 -
 -
 361
 -
 -
 113
 -
 -
 711
 -
 -
Tumor histology











     Ductal
 71,199
 72.3
 62.7
 13,981
 70.3
 12.3
 3,641
 74.4
 3.2
 24,722
 77.4
 21.8
     Lobular
 8,980
 9.1
 73.6
 2,160
 10.9
 17.7
 283
 5.8
 2.3
 784
 2.5
 6.4
     Ductal/Lobular
 7,576
 7.7
 76.7
 1,341
 6.7
 13.6
 233
 4.8
 2.4
 722
 2.3
 7.3
     Inflammatory
 543
 0.5
 37.8
 191
 1.0
 13.3
 90
 1.8
 6.3
 611
 1.9
 42.6
     Mucinous
 2,927
 3.0
 80.9
 486
 2.4
 13.5
 41
 0.8
 1.1
 164
 0.5
 4.5
     Tubular
 1,696
 1.7
 79
 327
 1.6
 15.2
 44
 0.9
 2.1
 79
 0.3
 3.7
     Comedo
 1,159
 1.2
 43.6
 318
 1.6
 12.0
 179
 3.6
 6.7
 1,003
 3.1
 37.7
     Medullary
 266
 0.3
 14.7
 148
 0.8
 8.2
 97
 2.0
 5.4
 1,292
 4.0
 71.7
     Papillary
 582
 0.6
 79.0
 58
 0.3
 7.9
 10
 0.2
 1.3
 87
 0.3
 11.8
     Other
 3,535
 3.6
 49.4
 876
 4.4
 12.2
 278
 5.7
 3.9
 2,466
 7.7
 34.5
Tumor stage











     I
 50,172
 52.4
 69.2
 9,232
 48
 12.7
 1,999
 42.7
 2.8
 11,114
 36.2
 15.3
     II
 37,335
 39.0
 60.3
 7,606
 39.5
 12.3
 2,068
 44.2
 3.3
 14,878
 48.4
 24.1
     III
 5,332
 5.5
 51.3
 1,471
 7.6
 14.1
 385
 8.2
 3.7
 3,210
 10.4
 30.9
     IV
 2,943
 3.1
 52.1
 936
 4.9
 16.6
 230
 4.9
 4.1
 1,536
 5.0
 27.2
     Unstaged
 2,681
 -
 -
 641
 -
 -
 214
 -
 -
 1,192
 -
 -
Tumor grade











     1
 18,012
 21.8
 81.1
 2,885
 17.5
 13.0
 405
 9.9
 1.8
 914
 3.3
 4.1
     2
 40,642
 49.3
 74.2
 7,133
 43.4
 13.0
 1,324
 32.5
 2.4
 5,682
 20.6
 10.4
     3
 22,082
 26.8
 44.4
 6,027
 36.6
 12.1
 2,174
 53.3
 4.4
 19,412
 70.4
 39.1
     4
 1,774
 2.1
 45.0
 413
 2.5
 10.5
 173
 4.3
 4.4
 1,579
 5.7
 40.1
     Unknown
 15,953
 -
3,428
 -
820
 -
4,343
 -
Tumor size (cm)











     0–1.9
 56,547
 59.9
 69.2
 10,302
 54.6
 12.6
 2,271
 49.5
 2.8
 12,576
 41.8
 15.4
     2–5
 32,977
 34.9
 58.7
 7,135
 37.8
 12.7
 1,891
 41.3
 3.4
 14,147
 47.1
 25.2
     >5
 4,949
 5.2
 48.8
 1,432
 7.6
 14.1
 422
 9.2
 4.2
 3,330
 11.1
 32.9
     Unknown
 3,990
 -
 -
 1,017
 -
 -
 312
 -
 -
 1,877
 -
 -
Axillary lymph node status











     Negative
 54,948
 65.3
 64.8
 10,428
 63.0
 12.3
 2,622
 61.0
 3.1
 16,749
 60.3
 19.8
     Positive
 29,234
 34.7
 60.9
 6,110
 37.0
 12.7
 1,675
 39.0
 3.5
 11,015
 39.7
 22.9
     Unknown
 14,281
 -
 -
 3,348
 -
 -
 599
 -
 -
 4,166
 -
 -
Surgical treatment











     Performed
 96,387
 98.0
 63.7
 19,216
 96.7
 12.7
 4,764
 97.4
 3.2
 30,847
 96.8
 20.4
     Not performed
 2,012
 2.0
 52.7
 648
 3.3
 17.0
 126
 2.6
 3.3
 1,032
 3.2
 27
     Unknown
 64
 -
 -
 22
 -
 -
 6
 -
 -
 51
 -
 -
Radiation therapy











     Treated
 46,859
 48.5
 65.5
 8,694
 44.5
 12.1
 2,048
 42.9
 2.9
 13,922
 44.8
 19.5
     None
 49,776
 51.5
 61.9
 10,836
 55.5
 13.4
 2,725
 57.1
 3.4
 17,131
 55.2
 21.3
     Unknown
 1,828
 -
 -
 356
 -
 -
 123
 -
 -
 877
 -
 -

ER, estrogen receptor; PR, progesterone receptor; SEER, Surveillance, Epidemiology, and End Results.

Dunnwald et al. Breast Cancer Research 2007 9:R6   doi:10.1186/bcr1639

Open Data